Archives

  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2018-07

    • EPZ-6438: Selective EZH2 Inhibitor for Epigenetic Cancer ...

    2026-01-05

    EPZ-6438: Selective EZH2 Inhibitor for Epigenetic Cancer Research

    Executive Summary: EPZ-6438 (A8221) is a nanomolar-potency EZH2 inhibitor that targets the polycomb repressive complex 2 (PRC2) and disrupts H3K27 trimethylation, a critical epigenetic mark for transcriptional repression and oncogenesis (Vidalina et al. 2025). The compound exhibits high selectivity for EZH2 over EZH1, with an IC50 of 11 nM and a Ki of 2.5 nM, and demonstrates nanomolar antiproliferative effects in SMARCB1-deficient malignant rhabdoid tumor (MRT) cell lines. EPZ-6438 modulates key gene expression (e.g., CD133, DOCK4, PTPRK, CDKN1A, CDKN2A, BIN1) in a time-dependent manner and shows dose-dependent antitumor efficacy in EZH2-mutant lymphoma xenograft models in SCID mice. The product is supplied by APExBIO, optimized for solubility in DMSO, and widely adopted in epigenetic pathway research (APExBIO product page).

    Biological Rationale

    The polycomb repressive complex 2 (PRC2) is a multi-protein complex that catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3), a key epigenetic mark associated with transcriptional silencing. The catalytic subunit, EZH2 (Enhancer of Zeste Homolog 2), is a histone methyltransferase frequently overexpressed in multiple cancers, including lymphomas and HPV-associated cervical carcinomas (Vidalina et al. 2025). Elevated EZH2 activity enforces oncogenic transcriptional programs by repressing tumor suppressor genes. Genetic or epigenetic dysregulation of EZH2 contributes to malignant transformation, proliferation, and metastatic potential. Inhibiting EZH2 activity, therefore, provides a targeted approach to reverse aberrant gene silencing and reduce oncogenicity. EPZ-6438 is designed to achieve specific inhibition of EZH2, thereby enabling precise interrogation of PRC2-dependent pathways in cancer biology (see also; this article extends the scope to translational models and in vivo data).

    Mechanism of Action of EPZ-6438

    EPZ-6438 is a competitive inhibitor that binds to the S-adenosylmethionine (SAM) binding pocket of EZH2, blocking methyl group transfer to H3K27. This results in inhibition of H3K27 trimethylation (H3K27me3), a repressive histone mark. The compound displays high selectivity for EZH2 over the related enzyme EZH1, minimizing off-target effects. Upon EPZ-6438 treatment, global levels of H3K27me3 are reduced in a dose- and time-dependent manner, leading to derepression of tumor suppressor genes and reactivation of cell cycle checkpoints (related dossier; this article provides additional gene expression and in vivo efficacy data). In cell models, EPZ-6438 induces G0/G1 cell cycle arrest and apoptosis, particularly in tumors with EZH2 gain-of-function mutations or PRC2 pathway dependencies (Vidalina et al. 2025).

    Evidence & Benchmarks

    • EPZ-6438 exhibits an in vitro IC50 of 11 nM and Ki of 2.5 nM for EZH2, with >100-fold selectivity over EZH1 (APExBIO).
    • Reduces global H3K27me3 levels in cancer cell lines in a concentration-dependent manner (Vidalina et al. 2025, Fig. 2).
    • Induces G0/G1 cell cycle arrest and increased apoptosis in both HPV-positive and HPV-negative cervical cancer cells (Vidalina et al. 2025, Table 1).
    • Downregulates EZH2 and HPV16 E6/E7 oncoprotein expression at mRNA and protein levels while upregulating tumor suppressors p53 and Rb (Vidalina et al. 2025, Fig. 3).
    • In vivo, demonstrates dose-dependent tumor regression in EZH2-mutant lymphoma xenografts in SCID mice (dossier, in vivo section).
    • Modulates expression of cancer-relevant genes (CD133, DOCK4, PTPRK, CDKN1A, CDKN2A, BIN1) in a time-dependent manner (APExBIO).
    • EPZ-6438 (A8221) is solid at room temperature, soluble at ≥28.64 mg/mL in DMSO, and should be stored desiccated at -20°C for optimal stability (APExBIO).

    For a deeper dive into cell viability and assay design strategies using EPZ-6438, see this scenario-driven guide; the present article clarifies quantitative efficacy and workflow parameters for translational research.

    Applications, Limits & Misconceptions

    EPZ-6438 is widely used as a chemical probe for dissecting EZH2-dependent epigenetic processes in oncology, stem cell biology, and developmental regulation. It is particularly valuable in models of: (a) SMARCB1-deficient malignant rhabdoid tumors, (b) EZH2-mutant lymphomas, and (c) HPV-associated cervical cancers (Vidalina et al. 2025). The compound is not effective in models lacking PRC2/EZH2 dependency or in systems where H3K27 methylation is not a driver of pathogenesis. Misconceptions around off-target effects are minimized by its >100-fold selectivity for EZH2 over EZH1, but non-specific cytotoxicity may occur at supraphysiological concentrations. Quantitative efficacy is best observed in systems with genetically or epigenetically defined EZH2 activity. For advanced translational guidance, see this strategic deployment article; the current review updates efficacy and selectivity claims with new cervical cancer data.

    Common Pitfalls or Misconceptions

    • EPZ-6438 is not a pan-methyltransferase inhibitor; it displays minimal activity against EZH1 or other histone methyltransferases.
    • It does not reverse established DNA methylation marks or act on non-histone proteins.
    • Antiproliferative effects are limited in cell lines lacking PRC2/EZH2 dependency.
    • Solubility is restricted to DMSO; it is insoluble in ethanol and water.
    • Prolonged solution storage or exposure to moisture/room temperature reduces potency; fresh DMSO aliquots and desiccated storage at -20°C are recommended.

    Workflow Integration & Parameters

    EPZ-6438 (A8221) from APExBIO is provided as a solid, with optimal solubility at ≥28.64 mg/mL in DMSO. For highest reproducibility, solutions should be freshly prepared, warmed to 37°C, or sonicated to ensure dissolution. The compound is incompatible with water and ethanol-based vehicles. For in vitro studies, nanomolar dosing is typical (10–500 nM), while in vivo protocols require dose titration based on model system and tumor burden.

    Recommended storage is desiccated at -20°C; solutions are for short-term use only. Assays should include vehicle and off-target controls. Quantification of H3K27me3 by immunoblot or mass spectrometry is standard for monitoring efficacy. For extended workflow strategies, refer to this workflow guide; this article details nuanced storage and solubility recommendations.

    Conclusion & Outlook

    EPZ-6438 is a benchmark tool for dissecting PRC2/EZH2-mediated epigenetic regulation in cancer and developmental biology. Its nanomolar selectivity and robust in vitro and in vivo efficacy provide researchers with a reliable probe for transcriptional reprogramming studies. With validated performance in multiple disease models, including HPV-associated cervical cancer, the compound will remain central to studies of histone methyltransferase inhibition. For product specifications, ordering, and application notes, visit the EPZ-6438 product page at APExBIO.